Leerink Partners Upgrades ARS Pharmaceuticals Inc (SPRY) to Outperform
Tweet
Share
E-mailGet Alerts SPRY Hot Sheet
Price: $5.95 +5.31%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 20 | New: 20
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 20 | New: 20
Join SI Premium – FREE
Leerink Partners analyst Roanna Ruiz upgraded ARS Pharmaceuticals Inc (NASDAQ: SPRY) from Market Perform to Outperform with a price target of $18.00 (from $6.00).
For an analyst ratings summary and ratings history on ARS Pharmaceuticals Inc click here. For more ratings news on ARS Pharmaceuticals Inc click here.
Shares of ARS Pharmaceuticals Inc closed at $8.65 yesterday.
You May Also Be Interested In
- Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
- Info Edge India (INFOE:IN) PT Raised to INR1,260 at Macquarie
- JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
